趋化因子配体18及微血管密度在乳腺癌组织中的表达及意义  

The expression and significance of CCL18 and microvessel density in breast cancer

作　　者：高进[1] 唐炜[1] 叶熹罡[1] 陈伦[1] 林晓明[1] 潘凌霄[1] 张晓申[1] 郑文博[1] 

机构地区：[1]广州医学院第一附属医院乳腺外科,510120

出　　处：《中华临床医师杂志（电子版）》2013年第2期82-84,共3页Chinese Journal of Clinicians(Electronic Edition)

基　　金：广东省科技计划项目(2010B060900094)

摘　　要：目的探讨趋化因子配体18(CCL18)、肿瘤微血管密度(MVD)在乳腺癌组织中的表达及意义。方法选取我院乳腺外科2009年12月至2012年6月,病理确诊为乳腺癌患者组织标本51例,良性乳腺病患者组织标本42例,另取良性乳腺病患者病灶周边的正常乳腺组织16例作为对照组,全部入组病例为女性。采用免疫组化Envision方法,检测标本中CCL18、CD34的表达。结果 CCL18在对照组、良性乳腺病组均无表达,在乳腺癌组有38例为阳性,阳性率为74.51%;CCL18在乳腺癌组的表达与对照组及良性乳腺病组有统计学差异(P=0.00)。在CCL18表达阳性的38例乳腺癌患者中,CCL18的表达水平随乳腺癌临床分期的升高而升高(P=0.02)。MVD在对照组为(5.92±2.76)个/HP,在良性乳腺病组为(7.58±3.53)个/HP,在乳腺癌组为(35.13±15.06)个/HP;MVD在良性乳腺病组表达与对照组比较无差异(P=0.095),而在乳腺癌组的表达较对照组以及良性乳腺病组均明显升高(P=0.00)。在乳腺癌患者组中,CCL18表达阳性组较CCL18表达阴性组,MVD表达显著升高(P=0.016)。结论 CCL18、MVD均是乳腺癌的生物学指标,CCL18与肿瘤微血管的形成和肿瘤的浸润性及转移有一定的关系,对认识乳腺癌的生物学特性以及对指导乳腺癌的诊疗、预后具有重要意义。Objective To investigate the expression and significance of CCL18 and tumor microvessel （MVD） in breast cancer. Methods We collected 51 tissue samples from patients with breast cancer,42 tissue samples from patients with benign breast diseases, and 16 healthy tissue samples aside the benign lesions from the patients with benign breast disease as control group. All of the cases collected were female, in the department of breast surgery of our hospital from December 2009 to June 2012. Envision immunohistochemical method was used to examine the expressions of CCL18 and CD34. Results There were no CCL18 expressed in the control group and the benign breast diseases group, but there were 38 cases were positive in the breast cancer group, positive rate was 74. 51% ;Obviously, the expression level of CCL18 in the breast cancer group was higher than the other two groups, （P =0.00 ,P 〈0.05） ,and there was a positive correlation between the level of CCL18 and tumor staging,in the 38 breast cancer cases （ P = 0. 02）. The MVD was （5.92 ±2.76） pieces per highpower field in the control group, （7.58 ± 3.53 ）pieces per highpower field in the benign breast diseases group, and（35.13 ± 15.06 ）pieces per highpower field in the breast cancer group ;There were no differences of MVD in the control group and the benign breast diseases group（P = 0. 095）, but the MVD in the breast cancer group was higher than the control group and the benign breast diseases group（ P = 0.00）. The expression of MVD in the patients with breast cancer in which group CCL18 was positive was higher than the patients with breast cancer in which group CCL18 was negative （ P = 0. 016 ）. Conclusions Both of CCL18 and MVD are the markers of breast cancer,and the high expression of CCL18 in breast cancer have relationship with tumor angiogenesis and tumor invasion mad metastasis. That is important for us to know the bionomics of breast cancer, and useful for the treatment and prognosis of breast cancer.

关 键 词：乳腺肿瘤 趋化因子CCL18 抗原 CD34 微血管密度 

分 类 号：R737.9[医药卫生—肿瘤]